Clear Search

Showing 1 result for “Canovatchel W” published 2022.

January 2022

Efficacy and Safety of Canagliflozin Versus Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin (CANTATA-SU): 52 Week Results From a Randomised, Double-blind, Phase 3 Non-inferiority Trial

Lancet 2013;382:941–50 doi.org/10.1016/S0140-6736(13)60683-2

In the CANTATA-52 trial, canagliflozin was non-inferior to glimepiride for the primary endpoint of glucose-lowering at 52 weeks – and the highest dose achieved superiority.

more…